Evidence map›Paper›PMID 41216268›Full record

ArticleInternational journal of pharmaceutics: X2025

Iron-doped Zif-8 nanoplatform for MRI-guided synergistic microwave thermal/chemodynamic therapy of triple-negative breast cancer.

Zhenyu Xiang, Jialing Liu, Yan Zhang, Ru Shen, Ying Lu, Rong Li, Qinying Shi, Guannan Zhang, Sijin Li, Jianbo Song

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of pharmaceutics: X, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhenyu XiangDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Key Laboratory of Molecular Imaging, Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, PR China.
Jialing LiuShanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan 030032, PR China.
Yan ZhangDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Key Laboratory of Molecular Imaging, Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, PR China.
Ru ShenDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Key Laboratory of Molecular Imaging, Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, PR China.
Ying LuShanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan 030032, PR China.
Rong LiShanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan 030032, PR China.
Qinying ShiShanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan 030032, PR China.
Guannan ZhangShanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan 030032, PR China.
Sijin LiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Key Laboratory of Molecular Imaging, Collaborative Innovation Center for Molecular Imaging of Precision Medicine, Shanxi Medical University, Taiyuan 030001, Shanxi Province, PR China.
Jianbo SongShanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Taiyuan 030032, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC), a highly refractory malignancy characterized by aggressive clinical behavior, poses a significant therapeutic challenge due to its resistance to conventional treatments. While microwave thermal therapy (MWTT) emerges as a promising modality for TNBC treatment through deep-tissue penetration and uniform energy delivery, its reliance on prolonged hyperthermia exposure risks collateral damage to adjacent healthy tissues. Herein, we present a rationally engineered iron-doped zeolitic imidazolate framework-8 nanoplatform (Fe@Zif-8). This study aimed to develop a theranostic agent for MRI-guided combination therapy by pursuing the following objectives: (1) synthesizing and characterizing Fe-doped ZIF-8; (2) evaluating the enhancement of microwave thermal conversion efficiency

Indexed as

Chemodynamic therapyMagnetic resonance imagingMetal-organic frameworkMicrowave thermal therapyTriple-negative breast cancer

Identifiers

PMID41216268
PMCPMC12597300

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.